Picture of Lakefront Biotherapeutics NV logo

LKFT Lakefront Biotherapeutics NV News Story

0.000.00%
nl flag iconLast trade - 00:00
HealthcareBalancedMid CapSuper Stock

Brief: Galapagos Reports Third Quarter 2023 Results And Releases New Data From Car-T Studies For Presentation At Ash 2023

Nov 2 (Reuters) - Galapagos NV  GLPG.AS :
    * GALAPAGOS REPORTS THIRD QUARTER 2023 RESULTS AND RELEASES
NEW
ENCOURAGING DATA FROM CAR-T STUDIES FOR PRESENTATION AT ASH 2023
    * GALAPAGOS NV - 9M GROUP REVENUES OF EUR 448.9 MILLION, UP
9%
    * GALAPAGOS-SIGNED LETTER OF INTENT TO TRANSFER JYSELECA
BUSINESS
TO ALFASIGMA, INCLUDING EUROPE & UK MARKETING AUTHORIZATIONS &
DEVELOPMENT ACTIVITIES
    * GALAPAGOS - REITERATE FY 2023 NET SALES GUIDANCE FOR
JYSELECA OF
EUR 100-EUR 120 MILLION AND FY 2023 CASH BURN GUIDANCE IN RANGE
OF EUR 380-EUR 420 MILLION

Source text for Eikon:  ID:nGNXbHQ8Ns 
Further company coverage:  GLPG.AS 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Lakefront Biotherapeutics NV

See all news